Statistics

Total Visits

Views
Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months16

Select a period of time:

Number of views in the range

Views
Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months8

Views

Views
May 20241
June 20241
July 20242
August 20241
September 20243
October 20240
November 20240
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States8
 

Top cities views

Views
Chicago2
Gallatin1